BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Prognosis
258 results:

  • 1. FBXO32-mediated degradation of PTEN promotes lung adenocarcinoma progression.
    Wu J; Wen T; Marzio A; Song D; Chen S; Yang C; Zhao F; Zhang B; Zhao G; Ferri A; Cheng H; Ma J; Ren H; Chen QY; Yang Y; Qin S
    Cell Death Dis; 2024 Apr; 15(4):282. PubMed ID: 38643215
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mtor signaling axis by binding to MYH9.
    Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
    Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. High-content analysis identified synergistic drug interactions between INK128, an mtor inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line.
    Wang S; Oliveira-Silveira J; Fang G; Kang J
    BMC Cancer; 2024 Mar; 24(1):335. PubMed ID: 38475728
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. G protein-coupled estrogen receptor activates PI3K/AKT/mtor signaling to suppress ferroptosis via SREBP1/SCD1-mediated lipogenesis.
    Chen J; Zhao R; Wang Y; Xiao H; Lin W; Diao M; He S; Mei P; Liao Y
    Mol Med; 2024 Feb; 30(1):28. PubMed ID: 38383297
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. TMEM65 promotes gastric tumorigenesis by targeting YWHAZ to activate PI3K-Akt-mtor pathway and is a therapeutic target.
    Shi L; Wang X; Guo S; Gou H; Shang H; Jiang X; Wei C; Wang J; Li C; Wang L; Zhao Z; Yu W; Yu J
    Oncogene; 2024 Mar; 43(13):931-943. PubMed ID: 38341472
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Plin2 inhibits autophagy via activating AKT/mtor pathway in non-small cell lung cancer.
    Wang Y; Hu Y; Xu R; Jin X; Jiao W
    Exp Cell Res; 2024 Feb; 435(2):113955. PubMed ID: 38301990
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Unveiling the potential effects of resveratrol in lung cancer treatment: Mechanisms and nanoparticle-based drug delivery strategies.
    Najafiyan B; Bokaii Hosseini Z; Esmaelian S; Firuzpour F; Rahimipour Anaraki S; Kalantari L; Hheidari A; Mesgari H; Nabi-Afjadi M
    Biomed Pharmacother; 2024 Mar; 172():116207. PubMed ID: 38295754
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. DNA-PK-Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote lung Squamous Cell Carcinoma Malignancy and Chemoresistance.
    Wang H; Zhang Y; Tian Y; Yang W; Wang Y; Hou H; Pan H; Pei S; Zhu H; Gu Z; Zhang Y; Dai D; Chen W; Zheng M; Luo Q; Xiao Y; Huang J
    Cancer Res; 2024 Mar; 84(5):688-702. PubMed ID: 38199791
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The role of α7-nAChR-mediated PI3K/AKT pathway in lung cancer induced by nicotine.
    He Z; Xu Y; Rao Z; Zhang Z; Zhou J; Zhou T; Wang H
    Sci Total Environ; 2024 Feb; 912():169604. PubMed ID: 38157907
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. From carcinogenesis to therapeutic avenues: lncRNAs and mtor crosstalk in lung cancer.
    Hussain MS; Altamimi ASA; Afzal M; Almalki WH; Kazmi I; Alzarea SI; Saleem S; Prasher P; Oliver B; Singh SK; MacLoughlin R; Dua K; Gupta G
    Pathol Res Pract; 2024 Jan; 253():155015. PubMed ID: 38103364
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Abnormal low expression of SFTPC promotes the proliferation of lung adenocarcinoma by enhancing PI3K/AKT/mtor signaling transduction.
    Zuo B; Wang L; Li X; Li X; Wang J; Xiong Y; Lei J; Zhang X; Chen Y; Liu Q; Jiao J; Sui M; Fan J; Wu N; Song Z; Li G
    Aging (Albany NY); 2023 Nov; 15(21):12451-12475. PubMed ID: 37955668
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Comparison of gene mutation profile in different lung adenocarcinoma subtypes by targeted next-generation sequencing.
    Zhang S; Dong P; Pan Z; Chen Q; Zhu J; Mao Z
    Med Oncol; 2023 Nov; 40(12):349. PubMed ID: 37935925
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.
    Xia Y; Zhang L; He W; Pan H; Fang J; Cui G
    Cancer Biol Ther; 2023 Dec; 24(1):2271212. PubMed ID: 37906510
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. RUNX1 promotes proliferation and migration in non-small cell lung cancer cell lines via the mtor pathway.
    Ma H; Jiang S; Yuan Y; Li J; Li Y; Lv Y; Du T; Guan J; Jiang X; Tian L; Zheng Q; Yang L; Li Q
    FASEB J; 2023 Nov; 37(11):e23195. PubMed ID: 37801076
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. METTL3 exerts synergistic effects on m6A methylation and histone modification to regulate the function of VGF in lung adenocarcinoma.
    Shi K; Sa R; Dou L; Wu Y; Dong Z; Fu X; Yu H
    Clin Epigenetics; 2023 Sep; 15(1):153. PubMed ID: 37742030
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer.
    Liu H; Zhu Y; Niu H; Jie J; Hua S; Bai X; Wang S; Song L
    Cancer Med; 2023 Oct; 12(19):19777-19793. PubMed ID: 37732632
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Synergistic effect of Dactolisib/Lys05 combination on autophagy in A549 cells.
    Abdelwahab M; Saeed H; Elnikhely N; Nematalla H
    Acta Biochim Pol; 2023 Sep; 70(3):615-622. PubMed ID: 37677845
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. NQO1 drives glioblastoma cell aggressiveness through EMT induction via the PI3K/Akt/mtor/Snail pathway.
    Zheng L; Yang S; Xu R; Yang Y; Quan J; Lin Z; Quan C
    Int J Oncol; 2023 Oct; 63(4):. PubMed ID: 37594082
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α.
    Biziotis OD; Tsakiridis EE; Ali A; Ahmadi E; Wu J; Wang S; Mekhaeil B; Singh K; Menjolian G; Farrell T; Abdulkarim B; Sur RK; Mesci A; Ellis P; Berg T; Bramson JL; Muti P; Steinberg GR; Tsakiridis T
    Mol Oncol; 2023 Nov; 17(11):2235-2256. PubMed ID: 37584455
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. High expression of ENPP2 is an independent predictor of poor prognosis in liver cancer.
    Meng J; Ruan X; Wei F; Xue Q
    Medicine (Baltimore); 2023 Aug; 102(31):e34480. PubMed ID: 37543832
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 13.